RGEBX
Price
$82.44
Change
+$0.19 (+0.23%)
Updated
Sep 5 closing price
Net Assets
331.65B
URNQX
Price
$58.41
Change
+$0.06 (+0.10%)
Updated
Sep 5 closing price
Net Assets
7.8B
Interact to see
Advertisement

RGEBX vs URNQX

Header iconRGEBX vs URNQX Comparison
Open Charts RGEBX vs URNQXBanner chart's image
American Funds Growth Fund of Amer R2E
Price$82.44
Change+$0.19 (+0.23%)
VolumeN/A
Net Assets331.65B
Victory Nasdaq 100 Index R6
Price$58.41
Change+$0.06 (+0.10%)
VolumeN/A
Net Assets7.8B
RGEBX vs URNQX Comparison Chart in %
Loading...
View a ticker or compare two or three
VS
RGEBX vs. URNQX commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGEBX is a Buy and URNQX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RGEBX has more cash in the bank: 332B vs. URNQX (7.8B). URNQX pays higher dividends than RGEBX: URNQX (0.46) vs RGEBX (0.00). RGEBX was incepted earlier than URNQX: RGEBX (11 years) vs URNQX (9 years). RGEBX (1.09) is less costly to investors than URNQX (0.29). RGEBX is a more actively managed with annual turnover of: 25.00 vs. URNQX (22.00). URNQX has a lower initial minimum investment than RGEBX: URNQX (0) vs RGEBX (250). URNQX annual gain was more profitable for investors over the last year : 23.35 vs. RGEBX (17.32). URNQX return over 5 years is better than : 83.69 vs. RGEBX (38.39).
RGEBXURNQXRGEBX / URNQX
Total Expense Ratio1.090.29376%
Annual Report Gross Expense Ratio1.090.29376%
Fund Existence11 years9 years-
Gain YTD15.13212.841118%
Front LoadN/AN/A-
Min. Initial Investment2500-
Min. Initial Investment IRAN/AN/A-
Net Assets332B7.8B4,254%
Annual Yield % from dividends0.000.46-
Returns for 1 year17.3223.3574%
Returns for 3 years57.2485.9867%
Returns for 5 years38.3983.6946%
Returns for 10 years91.00N/A-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ARTV3.610.50
+16.08%
Artiva Biotherapeutics Inc
ARCT17.851.09
+6.50%
Arcturus Therapeutics Holdings
MANH215.315.45
+2.60%
Manhattan Associates
TRMD23.020.25
+1.10%
TORM plc
INDP3.30-1.31
-28.35%
Indaptus Therapeutics Inc